These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 34224442)

  • 1. Can HIV epidemics among MSM be eliminated through participation in preexposure prophylaxis rollouts?
    Jijón S; Molina JM; Costagliola D; Supervie V; Breban R
    AIDS; 2021 Nov; 35(14):2347-2354. PubMed ID: 34224442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination prospects of the Dutch HIV epidemic among men who have sex with men in the era of preexposure prophylaxis.
    Rozhnova G; Heijne J; Bezemer D; van Sighem A; Presanis A; De Angelis D; Kretzschmar M
    AIDS; 2018 Nov; 32(17):2615-2623. PubMed ID: 30379687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can the combination of TasP and PrEP eliminate HIV among MSM in British Columbia, Canada?
    Lima VD; Zhu J; Card KG; Lachowsky NJ; Chowell-Puente G; Wu Z; Montaner JSG
    Epidemics; 2021 Jun; 35():100461. PubMed ID: 33984688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the potential impact of pre-exposure prophylaxis for HIV among men who have sex with men in Cameroon.
    Lyons CE; Stokes-Cawley OJ; Simkin A; Bowring AL; Mfochive Njindam I; Njoya O; Bissek AZ; Tamoufe U; Georges S; Kakanou FZ; Turpin G; Levitt D; Billong SC; Mishra S; Baral S
    BMC Infect Dis; 2022 Sep; 22(1):751. PubMed ID: 36163000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving the "Ending the HIV Epidemic in the U.S." incidence reduction goals among at-risk populations in the South.
    Hamilton DT; Hoover KW; Smith DK; Delaney KP; Wang LY; Li J; Hoyte T; Jenness SM; Goodreau SM
    BMC Public Health; 2023 Apr; 23(1):716. PubMed ID: 37081482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM.
    Estcourt C; Yeung A; Nandwani R; Goldberg D; Cullen B; Steedman N; Wallace L; Hutchinson S
    AIDS; 2021 Mar; 35(4):665-673. PubMed ID: 33290298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
    Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
    AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.
    Mizushima D; Nagai Y; Mezzio D; Harada K; Piao Y; Barnieh L; El Moustaid F; Cawson M; Taniguchi T
    J Med Econ; 2023; 26(1):886-893. PubMed ID: 37421417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of PrEP on HIV Incidence Among Men Who Have Sex With Men in the Context of Condom Use, Treatment as Prevention, and Seroadaptive Practices.
    LeVasseur MT; Goldstein ND; Tabb LP; Olivieri-Mui BL; Welles SL
    J Acquir Immune Defic Syndr; 2018 Jan; 77(1):31-40. PubMed ID: 28961679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
    Ten Brink DC; Martin-Hughes R; Minnery ME; Osborne AJ; Schmidt HA; Dalal S; Green KE; Ramaurtarsing R; Wilson DP; Kelly SL
    PLoS One; 2022; 17(5):e0268240. PubMed ID: 35617169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
    Kazemian P; Costantini S; Kumarasamy N; Paltiel AD; Mayer KH; Chandhiok N; Walensky RP; Freedberg KA
    Clin Infect Dis; 2020 Feb; 70(4):633-642. PubMed ID: 30921454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Sweden: insights from a mathematical pair formation model.
    Hansson D; Strömdahl S; Leung KY; Britton T
    BMJ Open; 2020 Feb; 10(2):e033852. PubMed ID: 32029492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
    AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men.
    Ross EL; Cinti SK; Hutton DW
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):e61-7. PubMed ID: 26977749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
    Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
    BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?
    Wong NS; Kwan TH; Tsang OTY; Lee MP; Yam WC; Lam W; Leung WS; Chan JMC; Ho KM; Lee SS
    Sci Rep; 2018 Aug; 8(1):11641. PubMed ID: 30076362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased condom use among key populations using oral PrEP in Kenya: results from large scale programmatic surveillance.
    Manguro GO; Musau AM; Were DK; Tengah S; Wakhutu B; Reed J; Plotkin M; Luchters S; Gichangi P; Temmerman M
    BMC Public Health; 2022 Feb; 22(1):304. PubMed ID: 35164707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical modelling of the influence of serosorting on the population-level HIV transmission impact of pre-exposure prophylaxis.
    Wang L; Moqueet N; Simkin A; Knight J; Ma H; Lachowsky NJ; Armstrong HL; Tan DHS; Burchell AN; Hart TA; Moore DM; Adam BD; Macfadden DR; Baral S; Mishra S
    AIDS; 2021 Jun; 35(7):1113-1125. PubMed ID: 33534205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men - 20 Urban Areas, 2014 and 2017.
    Finlayson T; Cha S; Xia M; Trujillo L; Denson D; Prejean J; Kanny D; Wejnert C;
    MMWR Morb Mortal Wkly Rep; 2019 Jul; 68(27):597-603. PubMed ID: 31298662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.